{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:21:24Z","timestamp":1793136084515,"version":"4.5.0"},"reference-count":24,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2006,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Tefibazumab (Aurexis), a humanized monoclonal antibody that binds to the surface-expressed adhesion protein clumping factor A, is under development as adjunctive therapy for serious\n            <jats:italic>Staphylococcus aureus<\/jats:italic>\n            infections. Sixty patients with documented\n            <jats:italic>S. aureus<\/jats:italic>\n            bacteremia (SAB) were randomized and received either tefibazumab at 20 mg\/kg of body weight as a single infusion or a placebo in addition to an antibiotic(s). The primary objective of the study was determining safety and pharmacokinetics. An additional objective was to assess activity by a composite clinical end point (CCE). Baseline characteristics were evenly matched between groups. Seventy percent of infections were healthcare associated, and 57% had an SAB-related complication at baseline. There were no differences between the treatment groups in overall adverse clinical events or alterations in laboratory values. Two patients developed serious adverse events that were at least possibly related to tefibazumab; one hypersensitivity reaction was considered definitely related. The tefibazumab plasma half-life was 18 days. Mean plasma levels were &lt;100 \u03bcg\/ml by day 14. A CCE occurred in six patients (four placebo and two tefibazumab patients) and included five deaths (four placebo and one tefibazumab patient). Progression in the severity of sepsis occurred in four placebo and no tefibazumab patients. Tefibazumab was well tolerated, with a safety profile similar to those of other monoclonal antibodies. Additional trials are warranted to address the dosing range and efficacy of tefibazumab.\n          <\/jats:p>","DOI":"10.1128\/aac.00096-06","type":"journal-article","created":{"date-parts":[[2006,7,26]],"date-time":"2006-07-26T18:17:58Z","timestamp":1153937878000},"page":"2751-2755","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":135,"title":["Phase II, Randomized, Double-Blind, Multicenter Study Comparing the Safety and Pharmacokinetics of Tefibazumab to Placebo for Treatment of\n            <i>Staphylococcus aureus<\/i>\n            Bacteremia"],"prefix":"10.1128","volume":"50","author":[{"suffix":"Jr.","given":"J. John","family":"Weems","sequence":"first","affiliation":[{"name":"Greenville Hospital System University Medical Center, Greenville, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Steinberg","sequence":"additional","affiliation":[{"name":"Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Filler","sequence":"additional","affiliation":[{"name":"Harbor-UCLA Medical Center, Torrance, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Baddley","sequence":"additional","affiliation":[{"name":"UAB, Birmingham, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Ralph","family":"Corey","sequence":"additional","affiliation":[{"name":"DUMC, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Sampathkumar","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Winston","sequence":"additional","affiliation":[{"name":"University of California San Francisco, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"John","sequence":"additional","affiliation":[{"name":"VAMC Charleston, Charleston, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine J.","family":"Kubin","sequence":"additional","affiliation":[{"name":"Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Talwani","sequence":"additional","affiliation":[{"name":"Palmetto Health, Columbia, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Moore","sequence":"additional","affiliation":[{"name":"Privia, The Research Centers of Via Christi, Wichita, Kansas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Patti","sequence":"additional","affiliation":[{"name":"Inhibitex, Alpharetta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Hetherington","sequence":"additional","affiliation":[{"name":"Inhibitex, Alpharetta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Texter","sequence":"additional","affiliation":[{"name":"Inhibitex, Alpharetta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Wenzel","sequence":"additional","affiliation":[{"name":"Inhibitex, Alpharetta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violet A.","family":"Kelley","sequence":"additional","affiliation":[{"name":"Inhibitex, Alpharetta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Vance G.","family":"Fowler","sequence":"additional","affiliation":[{"name":"DUMC, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000091184.93122.09"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/345476"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/344326"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2.5.467"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.73.8.5229-5232.2005"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/314712"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.17.2066"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043252"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-10-200211190-00007"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.71.12.6864-6870.2003"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.1.25"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000050454.01978.3B"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/313753"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808203390806"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-005-1345-3"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1099\/13500872-141-4-937"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.60.4.1514-1523.1992"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1086\/323459"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.15.1756"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.959-962.2005"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.182"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1086\/313650"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/23.2.255"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1086\/421946"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00096-06","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00096-06","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T19:14:54Z","timestamp":1645470894000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00096-06"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["10.1128\/AAC.00096-06"],"URL":"https:\/\/doi.org\/10.1128\/aac.00096-06","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8]]},"assertion":[{"value":"2006-01-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2006-05-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2006-08-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}